Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 6,838 shares of the life sciences company’s stock after acquiring an additional 50 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Illumina were worth $2,080,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Next Capital Management LLC purchased a new stake in Illumina during the 2nd quarter worth approximately $25,000. Massey Quick Simon & CO. LLC increased its holdings in Illumina by 3,100.0% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 96 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 93 shares during the last quarter. North Star Investment Management Corp. purchased a new stake in Illumina during the 3rd quarter worth approximately $31,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Illumina during the 2nd quarter worth approximately $37,000. Finally, Trust Co. of Vermont increased its holdings in Illumina by 296.8% during the 3rd quarter. Trust Co. of Vermont now owns 123 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 92 shares during the last quarter. 91.14% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Mostafa Ronaghi sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $285.52, for a total transaction of $2,855,200.00. Following the completion of the transaction, the senior vice president now owns 86,585 shares in the company, valued at approximately $24,721,749.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles Dadswell sold 1,220 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $279.88, for a total value of $341,453.60. Following the transaction, the senior vice president now owns 5,386 shares of the company’s stock, valued at approximately $1,507,433.68. The disclosure for this sale can be found here. Insiders sold a total of 32,638 shares of company stock valued at $9,580,415 over the last quarter. Company insiders own 0.38% of the company’s stock.
Shares of NASDAQ ILMN traded down $0.27 during trading on Tuesday, reaching $294.73. The stock had a trading volume of 28,315 shares, compared to its average volume of 1,087,920. Illumina, Inc. has a one year low of $263.30 and a one year high of $380.76. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.15 and a current ratio of 6.82. The stock has a market cap of $43.13 billion, a PE ratio of 51.57, a P/E/G ratio of 2.17 and a beta of 1.03. The firm’s 50 day moving average price is $301.50 and its two-hundred day moving average price is $310.40.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.53. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The business had revenue of $907.00 million during the quarter, compared to the consensus estimate of $872.65 million. During the same period in the previous year, the business earned $1.52 EPS. The business’s quarterly revenue was up 6.3% on a year-over-year basis. On average, research analysts expect that Illumina, Inc. will post 6.44 earnings per share for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.